Shineway Pharmaceutical (02877.HK) reported revenue of RMB 1.731 billion for the first three quarters, a year-on-year decrease of 28.3%.

Zhitong Finance APP News, Shenwei Pharmaceutical (02877.HK) announced that, according to the unaudited management accounts for the nine months ended September 30, 2026, turnover was RMB 1.731 billion, a decrease of 28.3% compared with the same period in 2025, as follows: turnover of injection products decreased by 39.2% to RMB 478 million; turnover of soft capsule products decreased by 14.3% to RMB 289 million; turnover of granule products decreased by 10.1% to RMB 351 million; turnover of traditional Chinese medicine formula granule products decreased by 30.8% to RMB 503 million; and turnover of other dosage form products decreased by 36.9% to RMB 110 million. Analyzed by product dosage form, for the nine months ended September 30, 2026, injection products, soft capsule products, granule products and traditional Chinese medicine formula granule products accounted for approximately 27.6%, 16.7%, 20.3% and 29.0% of the Group's total turnover, respectively.